Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...
In a study of patients with advanced melanoma, the prevalence of cutaneous immune–related adverse events (cirAEs) associated with nivolumab/relatlimab combination therapy was 21.5%, with rash ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback